Use of Rituximab as an Off-Label Medication in Glomerular Diseases: Clinical Perspective

Objectives: The aim of this study was to review the use rituximab (RTX) and outcomes in immune-mediated glomerular diseases (glomerulonephritis [GN]) and to compare it to the established literature. Methods: Adult GN patients who received RTX between January 2014 and January 2018 in three public hos...

Full description

Saved in:
Bibliographic Details
Published in:Medical principles and practice 2022-05, Vol.31 (2), p.133-141
Main Authors: AlSahow, Ali, Al-Muhaiteeb, Abdullah, Nawar, Hani, AlHelal, Bassam, AlYousef, Anas, Abdallah, Emad, AbuShall, Ahmad, Elmekawi, Sameh, Meshal, Basem, AlQallaf, Ahmed, AlRajab, Heba
Format: Article
Language:English
Subjects:
Adult
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - drug therapy
Biopsy
Data collection
Disease
FDA approval
Glomerulonephritis - drug therapy
Glomerulonephritis, Membranous - drug therapy
Glomerulosclerosis, Focal Segmental - drug therapy
Hospitals
Humans
IgA Vasculitis
Immunoglobulin G4-Related Disease - drug therapy
Immunotherapy
Kidney Diseases
Monoclonal antibodies
Nephrosis, Lipoid - drug therapy
Off-Label Use
Original Paper
Patients
Proteinuria - drug therapy
Remission (Medicine)
Rituximab - therapeutic use
Statistical analysis
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives: The aim of this study was to review the use rituximab (RTX) and outcomes in immune-mediated glomerular diseases (glomerulonephritis [GN]) and to compare it to the established literature. Methods: Adult GN patients who received RTX between January 2014 and January 2018 in three public hospitals were reviewed. Membranous nephropathy (MN) and minimal change disease (MCD) were considered diseases with the literature supporting RTX use. Lupus nephritis (LN), primary focal segmental glomerulosclerosis (1 o FSGS), IgA nephropathy, IgG4-related disease (IgG4-RD), and C3GN had insufficient literature support for RTX use. Clinical remission was assessed 6 months after receiving RTX. Results: A total of 61 cases were analyzed. RTX was an add-on therapy in 87%. The remission rate was 95% in the MCD and MN versus 56% in the off-label group (p = 0.002). LN patients had a mean initial estimated glomerular filtration rate (eGFR) of 69 mL/min. All class III LN achieved remission, and 11 of 21 class IV achieved remission. The mean initial eGFR for 1 o FSGS was 33 mL/min, and it did not improve, and only 2 of 5 had partial resolution of proteinuria. Proteinuria improved in 3 of 5 IgG4-RD cases with eGFR stabilization but failed to improve in C3GN cases with eGFR deterioration. Vasculitis cases (6 ANCA-associated vasculitis and 2 IgA vasculitis) were analyzed separately. Remission was achieved in only 2 ANCA-associated vasculitis cases, and none in IgA vasculitis cases. Conclusions: Our data support the use of RTX in resistant MCD and MN. RTX showed success in LN and IgG4-RD but not FSGS or C3GN. The small number of cases of vasculitis does not allow drawing a conclusion on RTX effectiveness.
ISSN:1011-7571
1423-0151
DOI:10.1159/000521901